BioWorld

Oct. 16, 2002

Overdose Of Acetaminophen (Tylenol) Results In Hundreds Of Ruined Livers Each Year

Xerion, Arius Team Up On Effort To Develop Colon Cancer Drugs

Other News To Note

Waksal Pleads Guilty To Six Charges Related To Erbitux

Invitrogen Paying $47M In Cash For Software Provider InforMax

Invitrogen Corp. aims to create a "desktop to lab bench" tool set with its buyout of InforMax Inc. in an all-cash transaction valued at $1.36 per share, or about $42 million for the fully diluted equity. (BioWorld Today) Read More

European Officials Seek Unity To Help Challenge U.S. Position

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...